Investing in pharmaceutical products to treat hair loss and the potential risks associated with that, as well as other treatments such as Minoxidil, Finasteride, RU58841, and a COVID-19 booster.
PP405 and GT20029 are new hair loss treatments with different mechanisms from traditional options like Minoxidil and Finasteride. PP405 targets hair follicle stem cells to reactivate growth, while GT20029 works as an androgen receptor deleter, both requiring ongoing use for effectiveness.
The conversation discusses the potential benefits of creating a hydrophobic version of finasteride to reduce systemic side effects while maintaining scalp health. It compares this idea to fluridil, which is designed to be hydrophobic and has less systemic absorption.
The post discusses a new hair loss treatment involving an improved pyri formula that has shown promising results, including thicker hair and a restored hairline, with minimal side effects. The author seeks investors to collaborate with Kintor or acquire the pyri patent, offering equity rewards and complimentary samples for verification.
VDPHL01 shows faster and stronger hair growth compared to standard minoxidil, with no major side effects reported. Users discuss combining it with other treatments like dutasteride and finasteride for better results, while expressing skepticism about the effectiveness of PP405.
User discusses using trichosol as a vehicle for hair loss treatments like finasteride and minoxidil. They ask about others' experiences and the stability of the solutions.
New hair loss treatments, including Breezula, VDPHL01, and PP405, are nearing Phase 3 trials, offering hope for effective solutions. Current treatments like finasteride and minoxidil remain effective, but early intervention is crucial.
The conversation discusses concerns about using hair fibers while microneedling, specifically the potential for clogging pores. It is suggested that microneedling should not cause bleeding.
PP405 cannot restore extracted hair follicles after a transplant as they are removed, not dormant. Combining verteporphin with wounding and PP405 is suggested but not confirmed effective.
A potential baldness cure, possibly PP405, might be available before the release of GTA 6, which is delayed to 2026 or 2027. There is skepticism about the effectiveness and release timeline of PP405.
Scalp biopsies are crucial for diagnosing hair loss conditions like Diffuse Unpatterned Alopecia (DUPA) and retrograde hair loss, as treatments like finasteride and dutasteride may not be effective if other conditions are present. Combining PPAR-GAMMA agonists with retinoids could improve treatments for conditions like Lichen Planopilaris.
PP405 is considered as a potential hair regrowth treatment, but users are skeptical due to past product failures. They compare it to Minoxidil and Finasteride, questioning its effectiveness and the intentions of pharmaceutical companies.
Amino acids like lysine, methionine, and cysteine may help with androgenetic alopecia when taken in high doses along with a DHT blocker. Users discuss combining these with treatments like Minoxidil, finasteride, and RU58841.
The conversation discusses creating a topical melatonin solution for hair loss, with challenges in dissolving melatonin pills due to additives. Suggestions include using melatonin powder mixed with ethanol and glycerin.
A serum with oleic and palmitoleic acids shows promise for hair regrowth in mice, but its effectiveness in humans is unproven. Minoxidil and finasteride remain the recommended treatments.
A user reported that Procerin, containing Saw Palmetto and Pumpkin seed oil, provided similar hair thickening results as finasteride but with milder side effects. They experienced reduced libido and watery ejaculations but are adjusting the dose to minimize these effects.
The conversation discusses hair loss treatments, including finasteride, microneedling, minoxidil, and PTD-DBM. The user has not noticed significant regrowth and is considering cost-effective options like valproic acid.
Mixing 1ml of topical Minoxidil and Pyrilutamide (2ml total) together in a container and applying immediately is being discussed. The concern is whether this method degrades or compromises the efficacy of either compound.
The conversation discusses the optimal amount of Propylene Glycol in Minoxidil for better absorption. It focuses on enhancing the effectiveness of Minoxidil in treating hair loss.
The conversation is about the availability of the PP405 formula for hair loss treatment, with mentions of finasteride and its side effects. Users discuss the potential of obtaining the formula through unofficial channels and the challenges related to its genetic sequence and delivery method.
PP405 is in phase 2 trials for hair loss, with discussions on its cost and effectiveness compared to minoxidil and finasteride. Users are skeptical about its efficacy and timeline, with hopes for market release by 2027.
PP405 is viewed skeptically, with some seeing it as overhyped and potentially ineffective compared to existing treatments like minoxidil and finasteride. While it shows some promise in activating dormant hair follicles, many believe it won't replace hair transplants or significantly outperform current options.
Users discussed using GHK-Cu and AHK-Cu peptides with microneedling for hair loss, noting some small changes after 7-8 weeks. They mentioned continued shedding but no widening of the part.
Stacking 5% minoxidil twice daily, 1.25mg finasteride daily, 6 drops of the Ordinary hair serum with Redensyl each night, 1.5mm dermarolling once a week, Nizoral shampoo twice a week and caffeine shampoo once a week for hair loss treatment.
Calecim (PTT-6) Advanced Hair System is a 6-week hair restoration product using stem cell-derived ingredients to stimulate hair growth. Users are skeptical, calling it overpriced and ineffective, suggesting alternatives like LLLT devices or PRP treatments.
Breezula shows promising hair growth results, with up to 539% increase in hair count compared to placebo, and regulatory submissions are planned in the US and EU. Users are cautiously optimistic, noting the potential for Breezula to replace finasteride by targeting DHT without systemic effects.